SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results for the first quarter ended March 31, 2018. The Company also announced a corporate restructuring plan to streamline its operations as it focuses its development efforts on the further clinical advancement of ATYR1923.
Program Prioritization and Corporate Restructuring
aTyr has decided not to proceed with IND-enabling activities, including GMP manufacturing, for the panel of antibodies identified in its ORCA program, as pre-clinical data generated over the last month did not show sufficient e…
Read the full article at: https://globenewswire.com/news-release/2018/05/14/1501534/0/en/aTyr-Pharma-Announces-First-Quarter-2018-Operating-Results-Program-Prioritization-and-Corporate-Restructuring.html